Mertens, Joachim C.

Cholangiocarcinoma 2020: the next horizon in mechanisms and management

Banales, J. M., Marin, J. J. G., Lamarca, A., Rodrigues, P. M., Khan, S. A., Roberts, L. R., Cardinale, V., Carpino, G., Andersen, J. B., Braconi, C., et al. (2020) · Nature Reviews Gastroenterology & Hepatology

Cholangiocarcinoma and Gallbladder Cancer StudiesPediatric Hepatobiliary Diseases and Treatments

Cited by 2,411

NASH limits anti-tumour surveillance in immunotherapy-treated HCC

Pfister, D., Núñez, N. G., Pinyol, R., Govaere, O., Pinter, M., Szydlowska, M., Gupta, R., Qiu, M., Deczkowska, A., Weiner, A., et al. (2021) · Nature

Cancer Immunotherapy and BiomarkersHepatocellular Carcinoma Treatment and Prognosis

Cited by 1,294

The tumour microenvironment and immune milieu of cholangiocarcinoma

Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International

Cholangiocarcinoma and Gallbladder Cancer StudiesLiver Diseases and Immunity

Cited by 187

Targeting senescent cholangiocytes and activated fibroblasts with B‐cell lymphoma‐extra large inhibitors ameliorates fibrosis in multidrug resistance 2 gene knockout (Mdr2−/− ) mice

Moncsek, A., Al‐Suraih, M. S., Trussoni, C. E., O'Hara, S. P., Splinter, P. L., Zuber, C., Patsenker, E., Valli, P. V., Fingas, C. D., Weber, A., et al. (2018) · Hepatology

Liver Diseases and ImmunityLiver physiology and pathology

Cited by 136

Primary biliary cholangitis with normal alkaline phosphatase: A neglected clinical entity challenging current guidelines

Terziroli Beretta-Piccoli, B., Stirnimann, G., Mertens, J., Semela, D., Zen, Y., Mazzucchelli, L., Voreck, A., Kolbus, N., Merlo, E., Di Bartolomeo, C., et al. (2021) · Journal of Autoimmunity

Liver Diseases and ImmunityPediatric Hepatobiliary Diseases and Treatments

Cited by 39